Caco Laco - NNVC - it's a zero - Caco Laco - InvestorVillage

  • Important Upgrade Notice: 


    At 9 pm Central, Sunday 2/16/2020, we launched the following tools as Phase One of our Premium Plus service (full service package still under development): 

    1) Customizable Scrolling Ticker
    2) Portfolio Manager
    3) Stock-specific News & Trading Email Alert Notifications

    These products are immediately available to Precious Metal & Gemstone Patrons. 

    To watch a tutorial on the "regular" site, click here. On "premium," click here


This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: Caco Laco   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  28572 of 28584  at  10/31/2019 2:43:21 PM  by

akcje


 In response to msg 28571 by  S_Colton
view thread

Re: NNVC - it's a zero

 Ugh.  I have kept the shares, though due to their value, I've stopped following the company.   I guess I'm treating it now as an expensive  lottery ticket.      
It may add up to my collection of bankrupt companies :-( 
But has something changed recently?
I see only this in Yahoo news:
 
  • ACCESSWIRE6 days ago

    NanoViricides, Inc., Builds Promising Pipeline Targeting a Multi-Billion Dollar Market for Herpes and Shingles

    SHELTON, CT / ACCESSWIRE / October 25, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), is a development stage nano-biopharmaceutical Company focused on countering viral infections, which has developed a unique, proprietary nanomedicine technology. The Company is developing nanoviricide drug candidates against several commercially important viral diseases: seasonal and potentially-epidemic influenzas, bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses.

  • ACCESSWIRE22 days ago

    NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101

    SHELTON, CT / ACCESSWIRE / October 9, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in nanomedicines with novel platform technology to treat difficult and life-threatening viral diseases, announces that it has initiated bio-analytical studies as part of the required IND-enabling preclinical safety and toxicology studies of NV-HHV-101, moving towards human clinical trials. The Company has contracted NorthEast BioLab, Hamden CT, to conduct the bio-analytical studies and facilitate the toxicokinetic analyses. NorthEast BioLab has already performed the bio-analytical assay development and validation and is in the process of determining the concentrations of NV-HHV-101 in blood samples from the general safety and toxicology studies that are required for IND.

  • ACCESSWIRE28 days ago

    NanoViricides is Creating Nanomedicines to Develop Antiviral Therapies to Combat Shingles and Herpes Viruses Interviewing with Proactive Investors, President & Chairman Anil R. Diwan Outlines the History and Cutting Edge Technology Driving Proprietary Therapies

    SHELTON, CT / ACCESSWIRE / October 3, 2019 / NanoViricides, Inc., (NYSE American:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, based on the nanoviricides® platform, announces that Anil R. Diwan, PhD, President and Executive Chairman, was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. The Company recently announced that its first clinical drug candidate, NV-HHV-101, for the treatment of the Shingles virus (aka VZV), is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials.

  • ACCESSWIRElast month

    NanoViricides, Inc. Files Form S-1 Registration Statement

    SHELTON, CT / ACCESSWIRE / September 30, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announced today that it has filed a Form S-1 Registration Statement with the Securities and Exchange Commission ("SEC"). This Form S-1 will enable the Company to raise the necessary capital once it is declared effective by the SEC. Maxim Group LLC will serve as the Company's underwriter for the offering under this Form S-1.

    Simply Wall St.last month

    What Percentage Of NanoViricides, Inc. (NYSEMKT:NNVC) Shares Do Insiders Own?

    The big shareholder groups in NanoViricides, Inc. (NYSEMKT:NNVC) have power over the company. Insiders often own a...

 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 40
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...